A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years

Administered By

Surgery, Surgical Sciences

Awarded By

Moderna Therapeutics, Inc.

Contributors

Beerman, Rebecca Project Manager
Montefiori, David Charles Principal Investigator
Sarzotti-Kelsoe, Marcella Director
Shen, Xiaoying Co Investigator

Start/End

June 9, 2021 - June 9, 2023